# RIMKLA

## Overview
RIMKLA is a gene that encodes the ribosomal modification protein rimK like family member A, which functions as a protein kinase. This protein is involved in the post-translational modification of betaine-homocysteine S-methyltransferase 1 (BHMT1) through phosphorylation, playing a critical role in homocysteine metabolism and lipid regulation (Yan2024Ribosomal). RIMKLA is predominantly expressed in the liver, where it influences glucose and lipid metabolism by modulating the activity of key metabolic enzymes and transcription factors (Yan2024Ribosomal). The protein's activity is crucial for maintaining metabolic homeostasis and preventing disorders such as non-alcoholic fatty liver disease (NAFLD) and diabetes (Yan2024Ribosomal). Additionally, RIMKLA has implications in neurological health, with mutations affecting cognitive functions (Becker2021Mice).

## Function
RIMKLA, a ribosomal modification protein, functions as a protein kinase that phosphorylates betaine-homocysteine S-methyltransferase 1 (BHMT1) at the threonine 45 (Thr45) site. This phosphorylation is crucial for activating BHMT1, which plays a significant role in homocysteine metabolism by converting homocysteine to methionine, thereby maintaining normal homocysteine levels and preventing hyperhomocysteinemia (Yan2024Ribosomal). In the liver, RIMKLA's activity is associated with the regulation of glucose and lipid metabolism. It inhibits the transcription factor activator protein 1 (AP1), reducing the expression of fatty acid synthase (FASn) and cluster of differentiation 36 (CD36), which are involved in lipid synthesis and uptake. This action helps prevent hepatic lipid accumulation and steatosis (Yan2024Ribosomal).

RIMKLA is expressed in various tissues but is particularly important in the liver, where its expression is reduced under high-fat diet conditions, indicating its sensitivity to lipid-related metabolic changes (Yan2024Ribosomal). The protein's role in maintaining metabolic balance is crucial for preventing disorders associated with elevated homocysteine levels and excessive lipid accumulation, such as non-alcoholic fatty liver disease (NAFLD) and diabetes (Yan2024Ribosomal).

## Clinical Significance
Mutations or alterations in the expression of the RIMKLA gene have significant clinical implications, particularly in metabolic disorders. RIMKLA is involved in regulating homocysteine and lipid metabolism through its interaction with betaine-homocysteine S-methyltransferase 1 (BHMT1). Inhibition or deficiency of RIMKLA impairs BHMT1 activity, leading to increased homocysteine levels, glucose intolerance, and hepatic lipid deposition. These changes are associated with conditions such as hyperhomocysteinemia (HHcy), non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes mellitus (Yan2024Ribosomal).

RIMKLA expression is reduced in the livers of individuals with NAFLD, and its overexpression has been shown to ameliorate hepatic steatosis and hyperglycemia in obese mice. Conversely, RIMKLA deficiency exacerbates these conditions, highlighting its potential therapeutic role in managing NAFLD and related metabolic disorders (Yan2024Ribosomal).

In the context of neurological function, RIMKLA mutations can lead to reduced levels of N-acetylaspartylglutamate (NAAG) in the brain, affecting cognitive functions and memory. Mice deficient in RIMKLA exhibit impaired performance in memory tasks, suggesting a role for RIMKLA in neurological health (Becker2021Mice).

## Interactions
RIMKLA, a ribosomal modification protein, interacts with betaine-homocysteine S-methyltransferase 1 (BHMT1) through phosphorylation at the threonine 45 (Thr45) site. This interaction is crucial for activating BHMT1, which plays a significant role in hepatic lipid metabolism and homocysteine regulation. The phosphorylation of BHMT1 by RIMKLA enhances its enzymatic activity without altering its mRNA or protein levels, indicating a post-translational modification mechanism (Yan2024Ribosomal).

The interaction between RIMKLA and BHMT1 has been confirmed through co-immunoprecipitation assays and molecular docking predictions, which identified Thr45 as a key site at the interaction interface (Yan2024Ribosomal). This phosphorylation is essential for the repression of intracellular and extracellular homocysteine levels and the regulation of lipid metabolic genes such as fatty acid synthase (FASn) and CD36 (Yan2024Ribosomal).

RIMKLA's interaction with BHMT1 is significant in the context of nonalcoholic fatty liver disease (NAFLD), as it helps reduce hepatic lipid accumulation and ameliorate hyperglycemia by modulating lipid synthesis and uptake pathways (Yan2024Ribosomal).


## References


[1. (Becker2021Mice) Ivonne Becker, Lihua Wang‐Eckhardt, Julia Lodder‐Gadaczek, Yong Wang, Agathe Grünewald, and Matthias Eckhardt. Mice deficient in the naag synthetase ii gene rimkla are impaired in a novel object recognition task. Journal of Neurochemistry, 157(6):2008–2023, March 2021. URL: http://dx.doi.org/10.1111/jnc.15333, doi:10.1111/jnc.15333. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/jnc.15333)

[2. (Yan2024Ribosomal) Han Yan, Wenjun Liu, Rui Xiang, Xin Li, Song Hou, Luzheng Xu, Lin Wang, Dong Zhao, Xingkai Liu, Guoqing Wang, Yujing Chi, and Jichun Yang. Ribosomal modification protein rimk-like family member a activates betaine-homocysteine s-methyltransferase 1 to ameliorate hepatic steatosis. Signal Transduction and Targeted Therapy, August 2024. URL: http://dx.doi.org/10.1038/s41392-024-01914-0, doi:10.1038/s41392-024-01914-0. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41392-024-01914-0)